Identifying immunotherapeutic strategies for children with medulloblastoma

Zahra Abbas

doi:10.26182/nqzk-wp17

Identifying immunotherapeutic strategies for children with medulloblastoma

Zahra Abbas

School of Biomedical Sciences

Research output: Thesis › Doctoral Thesis

114 Downloads (Pure)

Abstract

Medulloblastoma is the most common malignant paediatric brain tumour, and clinical outcomes for group 3 medulloblastoma remain poor, prompting the need for new therapies. The purpose of this research is to investigate the immune microenvironment in Group 3 medulloblastoma to identify and assess immunotherapeutic approaches suitable for combination with existing treatments in paediatric medulloblastoma. Collectively, this work has provided the foundation to rationally design combination immunotherapies and has assessed a novel immunotherapy combination for medulloblastoma. Additionally, I have developed world-first paediatric models of medulloblastoma which provide new tools and perspectives in the development of paediatric-specific immunotherapies for medulloblastoma.

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	The University of Western Australia
Supervisors/Advisors	Endersby, Raelene, Supervisor Lesterhuis, Willem, Supervisor Johns, Terrance, Supervisor
Thesis sponsors	Australian Government Research Training Program
Award date	18 Jul 2024
DOIs	https://doi.org/10.26182/nqzk-wp17
Publication status	Unpublished - 2024

Access to Document

10.26182/nqzk-wp17

THESIS - DOCTOR OF PHILOSOPHY - ABBAS Zahra - 2024_
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.

1 Article

Conventional Therapies Deplete Brain-Infiltrating Adaptive Immune Cells in a Mouse Model of Group 3 Medulloblastoma Implicating Myeloid Cells as Favorable Immunotherapy Targets
Abbas, Z., George, C., Ancliffe, M., Howlett, M., Jones, A. C., Kuchibhotla, M., Wechsler-Reya, R. J., Gottardo, N. G. & Endersby, R., 3 Mar 2022, In: Frontiers in Immunology. 13, p. 837013 1 p., 837013.
Research output: Contribution to journal › Article › peer-review

Open Access
2 Citations (Scopus)

Cite this

@phdthesis{8410824320814f18ae5b87d4fc10314a,

title = "Identifying immunotherapeutic strategies for children with medulloblastoma",

abstract = "Medulloblastoma is the most common malignant paediatric brain tumour, and clinical outcomes for group 3 medulloblastoma remain poor, prompting the need for new therapies. The purpose of this research is to investigate the immune microenvironment in Group 3 medulloblastoma to identify and assess immunotherapeutic approaches suitable for combination with existing treatments in paediatric medulloblastoma. Collectively, this work has provided the foundation to rationally design combination immunotherapies and has assessed a novel immunotherapy combination for medulloblastoma. Additionally, I have developed world-first paediatric models of medulloblastoma which provide new tools and perspectives in the development of paediatric-specific immunotherapies for medulloblastoma.",

keywords = "Medulloblastoma, paediatric brain tumours, immunotherapy, CD47, preclinical models",

author = "Zahra Abbas",

year = "2024",

doi = "10.26182/nqzk-wp17",

language = "English",

school = "The University of Western Australia",

}

TY - BOOK

T1 - Identifying immunotherapeutic strategies for children with medulloblastoma

AU - Abbas, Zahra

PY - 2024

Y1 - 2024

N2 - Medulloblastoma is the most common malignant paediatric brain tumour, and clinical outcomes for group 3 medulloblastoma remain poor, prompting the need for new therapies. The purpose of this research is to investigate the immune microenvironment in Group 3 medulloblastoma to identify and assess immunotherapeutic approaches suitable for combination with existing treatments in paediatric medulloblastoma. Collectively, this work has provided the foundation to rationally design combination immunotherapies and has assessed a novel immunotherapy combination for medulloblastoma. Additionally, I have developed world-first paediatric models of medulloblastoma which provide new tools and perspectives in the development of paediatric-specific immunotherapies for medulloblastoma.

AB - Medulloblastoma is the most common malignant paediatric brain tumour, and clinical outcomes for group 3 medulloblastoma remain poor, prompting the need for new therapies. The purpose of this research is to investigate the immune microenvironment in Group 3 medulloblastoma to identify and assess immunotherapeutic approaches suitable for combination with existing treatments in paediatric medulloblastoma. Collectively, this work has provided the foundation to rationally design combination immunotherapies and has assessed a novel immunotherapy combination for medulloblastoma. Additionally, I have developed world-first paediatric models of medulloblastoma which provide new tools and perspectives in the development of paediatric-specific immunotherapies for medulloblastoma.

KW - Medulloblastoma

KW - paediatric brain tumours

KW - immunotherapy

KW - CD47

KW - preclinical models

U2 - 10.26182/nqzk-wp17

DO - 10.26182/nqzk-wp17

M3 - Doctoral Thesis

ER -

Identifying immunotherapeutic strategies for children with medulloblastoma

Abstract

Access to Document

Fingerprint

Research output

Conventional Therapies Deplete Brain-Infiltrating Adaptive Immune Cells in a Mouse Model of Group 3 Medulloblastoma Implicating Myeloid Cells as Favorable Immunotherapy Targets

Cite this